Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

Summit Therapeutics has a pipeline candidate that could be more effective than Merck's Keytruda. It's a good start, but ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Merck (MRK) is one of the worst-performing stocks in the Dow Jones Industrial Average (DJIA) on Thursday. The US government ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck (MRK) ended the recent trading session at $110.18, demonstrating a -1.7% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

The Dow Jones Industrial Average is down Thursday afternoon with shares of Merck and Intel seeing the biggest declines for the price-weighted average. Shares of Merck and Intel have contributed to the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...